Australia markets open in 6 hours 23 minutes

    -67.80 (-0.83%)

    +0.0015 (+0.22%)
  • ASX 200

    -66.90 (-0.85%)
  • OIL

    +0.77 (+0.97%)
  • GOLD

    +34.30 (+1.44%)
  • Bitcoin AUD

    -100.33 (-0.10%)
  • CMC Crypto 200

    -13.42 (-0.98%)

TFF Pharmaceuticals Full Year 2023 Earnings: Misses Expectations

TFF Pharmaceuticals (NASDAQ:TFFP) Full Year 2023 Results

Key Financial Results

  • Net loss: US$21.2m (loss narrowed by 33% from FY 2022).

  • US$11.85 loss per share (improved from US$26.49 loss in FY 2022).


All figures shown in the chart above are for the trailing 12 month (TTM) period

TFF Pharmaceuticals Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 1.2%.

Looking ahead, revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in the US.


Performance of the American Pharmaceuticals industry.

The company's shares are down 18% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 5 warning signs for TFF Pharmaceuticals (3 are significant!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.